NewLink Genetics Corp. (NASDAQ:NLNK)’s share price was up 2.9% during trading on Monday . The stock traded as high as $10.47 and last traded at $10.35, with a volume of 121,899 shares traded. The stock had previously closed at $10.06.

Several equities analysts have recently commented on NLNK shares. Robert W. Baird reissued an “outperform” rating and issued a $23.00 target price (down previously from $27.00) on shares of NewLink Genetics Corp. in a report on Tuesday, May 10th. Zacks Investment Research raised shares of NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Tuesday, July 5th. Mizuho lowered their target price on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, May 10th. Cantor Fitzgerald reissued a “buy” rating and issued a $62.00 target price on shares of NewLink Genetics Corp. in a report on Friday, April 29th. Finally, Jefferies Group reissued a “hold” rating and issued a $10.00 target price on shares of NewLink Genetics Corp. in a report on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. NewLink Genetics Corp. has a consensus rating of “Hold” and a consensus target price of $23.29.

The stock’s 50 day moving average price is $10.85 and its 200-day moving average price is $14.51. The firm’s market cap is $309.58 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last issued its quarterly earnings data on Friday, July 29th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by $0.35. On average, analysts forecast that NewLink Genetics Corp. will post ($3.06) EPS for the current year.

An institutional investor recently raised its position in NewLink Genetics Corp. stock. Dimensional Fund Advisors LP boosted its position in NewLink Genetics Corp. (NASDAQ:NLNK) by 0.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 48,507 shares of the company’s stock after buying an additional 300 shares during the period. Dimensional Fund Advisors LP owned 0.17% of NewLink Genetics Corp. worth $1,765,000 as of its most recent filing with the SEC.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.